HemaCare Earns $204,633 on 36% Increase in Revenue

HemaCare, a Sherman Oaks provider of blood-related products and services, reported a profit of $204,633, or 7 cents a share, in the third quarter that ended Sept. 30, compared with an $89,173 loss a year ago.

HemaCare, whose revenue jumped 36% to $1.2 million from $864,976, attributed the earnings turnaround largely to increased revenue from its therapeutic hemapheresis treatments in the Los Angeles area.

The treatments remove harmful substances from the blood, and are given to patients with leukemia, multiple sclerosis and other diseases.

For the first nine months of this year, HemaCare earned $359,275, or 12 cents a share, in contrast to a year-earlier loss of $393,047. Nine-month revenue rose to $3.35 million from $2.38 million.

For detailed data and results of other companies, please see tables, Page 13.